Cargando…

Real-World Treatment Persistence with Biologic Disease-Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis—A Retrospective Database Study

INTRODUCTION: To investigate drug survival for biologic disease-modifying antirheumatic drugs (bDMARDs) in a real-world cohort of German adult biologic-naïve patients with psoriatic arthritis (PsA). METHODS: Claims data for patients with a diagnosis of PsA, a bDMARD claims record (index date) betwee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sewerin, Philipp, Borchert, Kathrin, Meise, Dominic, Schneider, Matthias, Mahlich, Jörg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991063/ https://www.ncbi.nlm.nih.gov/pubmed/33611778 http://dx.doi.org/10.1007/s40744-021-00286-z

Ejemplares similares

Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs
por: Sruamsiri, Rosarin, et al.
Publicado: (2018)

Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis
por: Nash, Peter, et al.
Publicado: (2021)

A population-based projection of psoriatic arthritis in Germany until 2050: analysis of national statutory health insurance data of 65 million German population
por: Wang, Jiancong, et al.
Publicado: (2023)

Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study
por: Huss, Viking, et al.
Publicado: (2023)

Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis – a systematic review
por: Kingsley, Gabrielle H, et al.
Publicado: (2015)

Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis
por: Gladman, Dafna D., et al.
Publicado: (2020)

Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease‐Modifying Antirheumatic Drug Treatment
por: Sparks, Jeffrey A., et al.
Publicado: (2019)

Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs
por: Zhang, Huabin F, et al.
Publicado: (2014)

Introduction of a Simplified Psoriatic Arthritis Magnetic Resonance Imaging Score (sPsAMRIS): A Potential Tool for Treatment Monitoring in Peripheral Psoriatic Arthritis
por: Abrar, Daniel B., et al.
Publicado: (2020)

Risk of psoriatic arthritis depending on age: analysis of data from 65 million people on statutory insurance in Germany
por: Deike, Madeline, et al.
Publicado: (2021)

Biologic Disease-Modifying Antirheumatic Drugs for Preventing Radiographic Progression in Psoriatic Arthritis: A Systematic Review and Network Meta-Analysis
por: Wang, Szu-Hsuan, et al.
Publicado: (2022)

DGEMRIC in the Assessment of Pre-Morphological Cartilage Degeneration in Rheumatic Disease: Rheumatoid Arthritis vs. Psoriatic Arthritis
por: Abrar, Daniel B., et al.
Publicado: (2021)

Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data
por: Steffen, Annika, et al.
Publicado: (2018)

Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan
por: Mahlich, Jörg, et al.
Publicado: (2016)

Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2
por: Strand, Vibeke, et al.
Publicado: (2021)

HLA Allele Prevalence in Disease-Modifying Antirheumatic Drugs-Responsive Enthesitis and/or Arthritis Not Fulfilling ASAS Criteria: Comparison with Psoriatic and Undifferentiated Spondyloarthritis
por: Favoino, Elvira, et al.
Publicado: (2021)

The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials
por: Denis, Agathe, et al.
Publicado: (2023)

Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs
por: Murage, Mwangi J, et al.
Publicado: (2022)

Medication persistence for psoriatic arthritis in a Brazilian real-world setting
por: Ribeiro da Silva, Michael Ruberson, et al.
Publicado: (2019)

Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis
por: Alegre-Sancho, Juan José, et al.
Publicado: (2023)

Real‐World Treatment Effectiveness of Disease‐Modifying Antirheumatic Drugs by Serostatus Among Patients With Rheumatoid Arthritis
por: Jin, Yinzhu, et al.
Publicado: (2023)

Differentiating rheumatoid and psoriatic arthritis: a systematic analysis of high-resolution magnetic resonance imaging features—preliminary findings
por: Abrar, Daniel B., et al.
Publicado: (2020)

Cartilage Degradation in Psoriatic Arthritis Is Associated With Increased Synovial Perfusion as Detected by Magnetic Resonance Imaging
por: Abrar, Daniel B., et al.
Publicado: (2020)

Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database
por: Sruamsiri, Rosarin, et al.
Publicado: (2018)

Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis
por: Kemper, Alex R, et al.
Publicado: (2012)

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)

Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
por: Best, Jennie H., et al.
Publicado: (2020)

In vitro evaluation of disease-modifying antirheumatic drugs against rheumatoid arthritis associated pathogens of the oral microflora
por: Kussmann, Manuel, et al.
Publicado: (2021)

Real-world treatment persistence in patients with rheumatoid arthritis initiating DMARDs in Germany—a health insurance claims data analysis
por: Fiehn, Christoph, et al.
Publicado: (2023)

Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs
por: KESKİN, Yaşar, et al.
Publicado: (2020)

Utilization Patterns of Disease-Modifying Antirheumatic Drugs in Elderly Rheumatoid Arthritis Patients
por: Jin, Xue-Mei, et al.
Publicado: (2014)

Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
por: Xia, Yunfei, et al.
Publicado: (2016)

The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis
por: Hasegawa, Eriko, et al.
Publicado: (2023)

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
por: Mease, Philip J., et al.
Publicado: (2023)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
por: Smolen, Josef S, et al.
Publicado: (2010)

Use of Disease-modifying Antirheumatic Drugs After Cancer Diagnosis in Rheumatoid Arthritis Patients
por: Joo, Young Bin, et al.
Publicado: (2022)

Association between use of disease-modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, rheumatoid arthritis, or psoriasis/psoriatic arthritis: a nationwide, population-based cohort study of 84,989 patients
por: Chen, Hsin-Hua, et al.
Publicado: (2017)

Association of Seropositivity and Mortality in Rheumatoid Arthritis and the Impact of Treatment With Disease‐Modifying Antirheumatic Drugs: Results From a Real‐World Study
por: Alemao, Evo, et al.
Publicado: (2020)

Treatment persistence of biologics among patients with psoriatic arthritis
por: Haddad, Amir, et al.
Publicado: (2021)

Treatment Persistence of Apremilast Among Patients with Psoriatic Arthritis
por: Haddad, Amir, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b03j6svecr438vm34pmttaa487